Compare Amgen, Inc. (AMGN) vs Taskus Inc (TASK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Taskus Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Taskus Inc trades at $5.46 (market cap $495.44M). The key difference: Amgen, Inc. is far larger — about 395.9× Taskus Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Taskus Inc pays none. Which is the better fit depends on your goals.
| AMGN | TASK | |
|---|---|---|
Market Cap | $196.12B | $495.44M |
Sector | Health | Technology |
52-Week High | $388.16 | $18.21 |
52-Week Low | $271.18 | $4.57 |
Enterprise Value | $241.41B | $891.14M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TaskUs (TASK) trades at $5.41, up 2.66% today, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals with a P/E of 4.79 and net income margin of 8.7%, while recent Q1 2026 earnings missed expectations. Revenue grew to $1.18 billion in 2025, and the company appointed a new CFO in June 2026.
The stock appears undervalued with a consensus price target of $9.50, offering significant upside potential. However, risks include recent earnings miss, competitive pressures in digital services, and potential market volatility. Analyst sentiment is mixed with 55% buy ratings but cautious technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
